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1. Introduction
Cancer immunotherapy and immunization are the next steps towards safe and effective cancer
treatment. Checkpoint blockade therapy, tumor-specific antibodies, adoptive cell therapies, viral
vectors for gene therapy or oncolysis, and diverse platforms of tumor vaccines are being applied in
clinics or are being tested in various stages of pre-clinical and clinical research.
In contrast to the prophylactic human papillomavirus (HPV) cancer vaccines, therapeutic vaccines
are meant for the treatment of cancer. While the prophylactic HPV vaccination aims at the induction of
virus-specific antibodies, therapeutic immunization aims at inducing tumor-specific adaptive immune
responses. To date, the therapeutic efficacy of most therapeutic cancer vaccines, in general, is lower
than expected, as based on preclinical studies. This limited clinical response may, amongst other
reasons, be due to (i) insufficient or inappropriate activation of antigen-specific immune effector cells
in cancer patients caused by immune tolerance or immune suppression, (ii) the immune suppressive
tumor microenvironment, (iii) limited homing and accumulation of immune effector cells into the
tumor, and (iv) limitations due to narrow-spectrum and highly specific adaptive immune responses,
which do not target the whole heterogeneous population of tumor cells [1,2]. Thus, research on further
improvements to pre-emptively increase the chance of therapeutic efficacy of cancer vaccines in the
clinic is still essential.
To this end, this issue focuses on providing a better understanding of the variables governing the
disease state of the patients, which in turn will reveal molecular targets that can be considered for a
strategic therapeutic design aimed at better clinical outcomes. Moreover, in this issue we learn how
individual statuses of the patients may have an impact of the clinical outcome mediated by therapeutic
vaccines or checkpoint therapy, thus demanding strategies that can be applied for personalized therapy.
2. Cancer: Understanding the Disease and Spotting Strategic Targets for
Therapeutic Immunization
Cancer is a diverse and complex disease caused by specific changes in the genome that contribute
to cell transformation, and therefore requires proper classification based on molecular and genetic
characteristics. The review by Tuyaerts and Amant gives an insight into endometrial stromal sarcomas
(ESS) by first providing an overview of the clinicopathological features of low-grade and high-grade
ESS based on molecular markers [3]. Despite these molecular differences, the authors indicate that a
common feature of both low-grade and high-grade ESS is recurrent chromosomal translocations that
may result in the fusion of genes involved in regulatory processes driving neoplastic transformation.
They argue that these translocation–fusion proteins can represent potent tumor antigens as they
are tumor-specific, many of these breakpoints are shared by several patients, and often required
for tumorigenesis. Accordingly, a road-map to determine and screen the immunogenicity of these
translocation-breakpoints in ESS is provided where prediction algorithms of peptide-HLA binding
and in vitro immunogenicity assay play a crucial role in defining the target antigens for therapy.
Vaccines 2020, 8, 596; doi:10.3390/vaccines8040596 www.mdpi.com/journal/vaccines
Vaccines 2020, 8, 596 2 of 5
As a practical approach to antigen selection and screening, Terbuch and Lopez write that
next-generation sequencing (NGS) can aid in the identification of individual mutations and could
pave the way for personalized cancer vaccines [4]. A major limitation pertaining to immunotherapy is
that the efficacy is limited to cancer patients with high-mutational burden and pre-existing immune
responses [5]. Screening antigens via NGS seems an interesting approach but requires extensive
research before it is put to practical use. A major challenge faced by NGS these days is the low prediction
accuracy of high-affinity binders by the existing algorithms, indicating that a multidisciplinary approach
in combination with bioinformatics is required for functional improvisation. The authors also comment
on how to improve against the challenges arising due to tumor evolution and loss of antigens, and on
determining the right combinations and schedule of immunotherapy in a personalized manner.
3. Immune Status of Individual Patients Impact the Therapeutic Efficacy in Terms of
Anti-Cancer Response
Recent literature from clinical research has demonstrated that initial patient status has a large
impact on the clinical endpoints, for better or worse. For example, in checkpoint immunotherapy,
it was observed that PDL1 status of patients correlates strongly with the observed efficacy and is
routinely used as a biomarker to predict efficacy [6]. In a similar approach, the immunocompetent
status of the patient has been studied and found to influence cell-based vaccination therapy as
described in the review by Lluesma et al. in this issue [7]. Viral vector based vaccines may suffer from
antibody-mediated anti-vector immune responses that impede the therapeutic outcomes. Additionally,
the presence of immune cells with a regulatory phenotype prove to be a challenge in the case of
stimulating a local immune response in the case of myeloid-derived suppressor cells and peripheral
immune responses regulated by regulatory T cells.
To better understand such anti-inflammatory and regulatory responses mediated by the immune
system, Van Ee et al. review the effect of BDCA1+CD14+ immunosuppressive cells in cancer and
argue that these cells can be targeted to restore therapeutic efficacy [8]. The authors provide an
insight into how the presence of BDCA1+CD14+ cells in patients may suppress the induced immune
response in an antigen-specific manner systemically and at the tumor site, whereas, BDCA1+CD14+
cells in dendritic cell (DC) vaccines may directly hamper vaccine efficacy. They review the presence
of BDCA1+CD14+ cells in solid cancers and their immune-suppressive functions, and evaluate the
presence of BDCA1+CD14+ cells in leukemic cancers, suggesting that the presence of BDCA1+CD14+
cells correlates with clinical features of acute and chronic myeloid leukemia. The authors comment
that further research in understanding the development of BDCA1+CD14+ cells is necessary to
determine specific targets and improve the efficacy of dendritic-cell based vaccines. In addition,
the earlier-mentioned review by Lluesma et al. dissects how observed ineffectiveness in anticancer
responses is dictated by the immunocompetent status of cancer patients, supporting progression of
cancer via mechanisms like immune evasion [7]. The authors argue that most of the trials apply
DC vaccines to patients with an advanced gynecological or breast cancer, which may be a factor
mediating low response rates in clinical settings. Alternatively, adjuvant settings of DC-based
vaccination report higher response rates as compared to metastatic settings in terms of tumor-specific
immunity. Ineffective stimulation of immune responses may occur due to impaired development of
DCs, immune-tolerance, and defects in peripheral blood DCs of cancer patients. Thus the authors
suggest the notion of vaccinating cancer patients with early-stage disease, when possible, to improve
response rates, while considering screening patients and assessment prior to vaccination. Simultaneous
boost via combinatorial therapy—e.g., checkpoint blockade—may improve the expected outcomes
in clinics. Further indications can be gained by studies focusing on the correlation of routes of
administration with objective clinical responses, and alternatively by screening for ideal vaccine vectors
designed to overcome the barriers of regulatory immune responses while maintaining a safe approach
to vaccination.
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4. Strategic Vaccine Design and Combinations Thereof
Generating a vector for therapeutic vaccination requires that it should be engineered to be safe
and efficacious. Thus, vector design becomes equally important to vaccine development as is epitope
screening and knowledge of the target disease. The present issue brings the opinion and insight of
various researchers on strategies currently used, and necessary future improvements in designing
ideal delivery vectors for therapeutic vaccination. Due to advances in the field of synthetic biology,
it has become possible to engineer DNA-based, RNA-based, bacterial chassis, and viral vectors for safe
and effective immunization. Each vector design is intended to bring together genetic components and
respective resources to function, including but not limited to the transcription-translation of antigens,
appropriate presentation, and the activation of target immune cells.
One such example reviewed by Flickinger et al. in this series is of an engineered bacterial
chassis—Listeria monocytogenes—that has demonstrated impressive therapeutic benefits in pre-clinical
models and have and are being tested in clinical trials for anti-cancer therapy [9]. Attenuated
Listeria strains have been developed via deletion or episomal replacement of virulence genes,
or via photochemical-inactivation of the bacterial vectors. These strategies of attenuation have
an advantage over heat-kill inactivation as they allow the vector to invade host cells and secrete
target antigens in the cytosol for antigen presentation, thereby inducing CD8+ T-cell responses.
Additionally, antigen-mediated antitumor responses can be enhanced via fusion with Listeria antigens,
such as Listeriolysin-O, ActA proteins, resulting in stronger antitumor immune response. Future
directions here seem to explore combination approaches using Lm vaccines with radio-/chemotherapy,
checkpoint blockade, or perhaps a heterologous boost of vaccination with viral vectors re-stimulating
antigen-specific immunity.
Pre-clinical and clinical research in the field of viral vectors for antigen delivery is comparatively
more advanced than other (bacterial) vector-based therapies. However, various studies to date have
faced multiple challenges to the application of viral vector-based vaccines in terms of anti-vector
antibody responses, T cell-specific responses, and subsequent resistance to virotherapy [10,11].
Consequently, vaccine design strategies have focused on improving tumor-associated antigen-specific
responses instead of anti-vector immunity. In this current issue, Chondronasiou et al. report one such
an improvement in stimulating anti-melanoma T cell mediated immunity by strategic engineering of
Adenoviral vectors to selectively target dendritic cells in skin and lymph nodes, and deliver melanoma
antigens (MART-1) for reshaping the subsequent immune responses [12]. The authors demonstrate the
possibility of an off-the-shelf DC-targeted Adenoviral therapy, made possible by a chimeric-design
between serotype-5 Adenoviral capsid and serotype-3 knob protein, and has an enhanced T cell
priming ability as compared to conventional infection strategies. However, the authors do indicate the
possibility of pre-existing anti-adenoviral immunity that can impair therapeutic efficacy, thus requiring
further research on these lines in future.
Apart from engineered microbial vaccines, cell-based immune therapies have gained increasing
attention for cancer treatment. T cell-based therapies, including CAR-T cells, have been favored due
to the possibility of autologous T cell generation, and persistence response against targeted epitopes
selected from a myriad of tumor-associated antigens. However, technical difficulties in obtaining a
large proportion of such cells from patients prove to be a major challenge these days [13]. To overcome
this obstacle, Xiong et al. explored the genetical engineering of hematopoietic stem cells (HSCs) in a
murine model that can be reprogrammed to develop into antigen OVA-specific T cells via cloning T
cell receptors into these HSCs [14]. Of note, the authors demonstrate that such OVA-specific T cells can
be effectively generated from HSC lineages and are capable of developing in vivo when combined
with proinflammatory signals while maintaining their specificity to induce anti-tumor responses.
5. Optimizing Therapeutic Vaccination by Combinatorial Approaches and Targeted Delivery
After vector design, research is focused on strategies of vaccine delivery and combinatorial
approaches to build-on the immune responses initiated by the vaccines. As an emerging strategy
Vaccines 2020, 8, 596 4 of 5
for targeted delivery of therapeutics, Thadi et al. describe an interesting approach of intraperitoneal
immunotherapy for metastasis of peritoneum in their review [15]. They discuss how, despite of
being a lethal diagnosis, peritoneal metastasis has an improved chance of positive outcomes due
to targeted delivery, made possible by intraperitoneal immunotherapy. Both clinical trial results
and preclinical experimental studies reviewed here have supported the notion of intraperitoneal
delivery of checkpoint therapy, EpCAM targeting antibodies, engineered-NK cell-based therapies,
CAR-T cells, and even virus- or dendritic cell-based therapies. In terms of combinatorial approaches
to improve vaccination-mediated immune responses, the review by Dutcher and Bilen provides
detailed information of pivotal trials in genitourinary malignancies utilizing cancer vaccines and
checkpoint combination [16]. The authors explain how active developments in the field of vaccination
for prostate, renal, and bladder cancers have shown promise in early development. However,
these autologous cell-based, DNA-based, or virus-based vaccines have remained from resulting in
expected clinical outcomes when applied as mono-therapies. Consequently, the authors argue that
a combinatorial approach to vaccination along with checkpoint blockade seems to be a rational
option, with already some pre-clinical observation supporting this statement. Future trials are awaited
with high expectations, provided the established good-performance of checkpoint therapy in clinics.
Such combinatorial approaches are aimed to restore the impaired immune responses due to the
regulatory tumor microenvironment and can potentially boost the efficacy profile of vaccines applied
prior as monotherapies.
Moreover, the efficacy of such engineered therapies also depends on features external to vaccine
design and delivery strategies. Therapeutic optimization, thus, is a difficult task and requires a systemic
understanding of the disease and its respective microenvironment. In cancer, such microenvironments
remain in a dynamic flux of processes involving tumor cells, stromal cells, and immune cells. A diverse
set of simultaneous interactions occur in such microenvironment that may result in tumor cell death,
or metastasis via immune evasion [17]. Soluble signals, coupled with membrane-based protein–ligand
interactions, are some of the most frequent and primary interaction studied by various research
groups. In addition to these, recent interest in vesicle-mediated communication has shed some
light on these complex, yet defining interaction that govern the clinical outcomes of the patients.
The review by Jella et al. in this issue provides an elaborate discussion on vesicle, especially exosome
biology, focusing on the role of exosomes in mediating intracellular communication and their ability in
influencing the immune system of patients for better or worse outcomes [18]. The authors comment
that this immunomodulatory role of exosomes in cancer can be exploited for therapy, where exosomes
potentially can be engineered for delivery of therapeutics or may also serve their function as indicative
biomarkers of therapeutic responses. Future research in the field of exosome biology seems promising
in the development of targeted therapy by modulating exosome selectivity, in designing homogeneous
populations of exosomes to decrease variability, and in developing strategies to load exosomes with
antigens, nucleotide-based therapeutics, chemical drugs, or protein-based signals to improve immune
responses in patients.
6. Conclusions
Vaccine technology has evolved to include a wide range of vectors, high-throughput methods
to screen immunodominant tumor-associated antigens, combinatorial strategies, and adaptations in
therapeutic administration based on individual patient requirements. However, tumor as a target also
evolves constantly and participates in the Darwinian arms-race via mechanisms of clonal selection
and immune evasion. With technological advances and development in bioengineering, thus it would
become important to focus on evolutionary stable strategies of therapy design that are aimed at being
effective despite spatiotemporal selection pressures and persist as a long-term mediator of protection
against diseases like cancer.
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